Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)

Phase 3

Completed

Conditions: Hepatitis B

Interventions: Biological: HBVAXPRO™

First Posted Date: 2020-07-29

Last Posted Date: 2022-07-27

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 207

Registration Number: NCT04490499

Locations: 🇫🇮
Porin rokotetutkimusklinikka ( Site 0008), Pori, Satakunta, Finland
🇫🇮
Tampereen yliopisto Kokkolan rokotetutkimusklinikka ( Site 0009), Kokkola, Mellersta Osterbotten, Finland
🇫🇮
Seinajoki Vaccine Research Center ( Site 0010), Seinajoki, Pohjanmaa, Finland

and more 7 locations

A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

Phase 4

Completed

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Drug: Pembrolizumab
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2020-07-28

Last Posted Date: 2024-11-22

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 101

Registration Number: NCT04489888

Locations: 🇺🇸
Washington University School of Medicine ( Site 0240), Saint Louis, Missouri, United States
🇺🇸
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0262), Mineola, New York, United States
🇺🇸
UPMC Hillman Cancer Center ( Site 0253), Pittsburgh, Pennsylvania, United States

and more 32 locations

A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)

Phase 2

Active, not recruiting

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Belzutifan

First Posted Date: 2020-07-28

Last Posted Date: 2025-02-11

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 154

Registration Number: NCT04489771

Locations: 🇺🇸
Weinberg Cancer Institute at Franklin Square ( Site 0007), Baltimore, Maryland, United States
🇺🇸
University of Texas Southwestern Medical Center at Dallas ( Site 0004), Dallas, Texas, United States
🇺🇸
Inova Schar Cancer Institute ( Site 0001), Fairfax, Virginia, United States

and more 45 locations

Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)

Phase 3

Completed

Conditions: Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9

Interventions: Biological: RotaTeq (V260)
Biological: IPV

First Posted Date: 2020-07-22

Last Posted Date: 2024-07-26

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 400

Registration Number: NCT04481191

Locations: 🇨🇳
Yangchun Center For Disease Prevention And Control ( Site 0001), Yangchun, Guangdong, China

Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)

Phase 3

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Olaparib
Drug: 5-FU
Drug: Bevacizumab
Drug: Capecitabine
Drug: Leucovorin/ levoleucovorin

First Posted Date: 2020-07-02

Last Posted Date: 2024-10-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 335

Registration Number: NCT04456699

Locations: 🇪🇸
Hospital Universitario Central de Asturias ( Site 1153), Oviedo, Asturias, Spain
🇺🇸
Providence Portland Medical Center ( Site 1400), Portland, Oregon, United States
🇺🇸
Oregon Health & Science University ( Site 1411), Portland, Oregon, United States

and more 126 locations

A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)

Phase 2

Completed

Conditions: Relapsed or Refractory Solid Tumors

Interventions: Drug: Lenvatinib

First Posted Date: 2020-06-25

Last Posted Date: 2025-03-13

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 127

Registration Number: NCT04447755

Locations: 🇿🇦
Cancercare Rondebosch Oncology ( Site 0575), Cape Town, Western Cape, South Africa
🇺🇸
Monroe Carell Jr. Children's Hospital at Vanderbilt ( Site 0102), Nashville, Tennessee, United States
🇧🇪
UZ Gent ( Site 0250), Gent, Oost-Vlaanderen, Belgium

and more 46 locations

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

Phase 2

Active, not recruiting

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Drug: Lenvatinib
Drug: Docetaxel
Biological: Pembrolizumab
Drug: Capecitabine
Drug: Paclitaxel
Drug: Cetuximab

First Posted Date: 2020-06-11

Last Posted Date: 2025-05-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 408

Registration Number: NCT04428151

Locations: 🇺🇸
Rush University Medical Center ( Site 1560), Chicago, Illinois, United States
🇺🇸
Cleveland Clinic Main ( Site 1598), Cleveland, Ohio, United States
🇺🇸
Boston Medical Center ( Site 1605), Boston, Massachusetts, United States

and more 117 locations

Frespaciguat (MK-5475) in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)

Phase 1

Withdrawn

Conditions: Coronavirus Disease 2019 (COVID-19)
Pneumonia
Hypoxemia

Interventions: Drug: Frespaciguat
Drug: Placebo

First Posted Date: 2020-06-11

Last Posted Date: 2025-05-15

Lead Sponsor: Merck Sharp & Dohme LLC

Registration Number: NCT04425733

Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)

Phase 3

Completed

Conditions: Pneumococcal Infections

Interventions: Biological: V114
Biological: PCV13

First Posted Date: 2020-05-12

Last Posted Date: 2023-07-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 694

Registration Number: NCT04384107

Locations: 🇯🇵
National Hospital Organization Sendai Medical Center ( Site 3311), Sendai, Miyagi, Japan
🇯🇵
INAMITSU Children's Clinic ( Site 3321), Fukuoka, Japan
🇯🇵
Fukui Aiiku Hospital ( Site 3315), Fukui, Japan

and more 42 locations

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Phase 3

Active, not recruiting

Conditions: Lung Neoplasms
Carcinoma, Non-Small-Cell Lung

Interventions: Biological: Pembrolizumab
Drug: Etoposide
Drug: Placebo for olaparib
Drug: Olaparib
Drug: Carboplatin
Drug: Cisplatin
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Durvalumab
Radiation: Thoracic Radiotherapy

First Posted Date: 2020-05-08

Last Posted Date: 2024-11-19

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 870

Registration Number: NCT04380636

Locations: 🇺🇸
Torrance Memorial Physician Network / Cancer Center ( Site 0093), Torrance, California, United States
🇺🇸
UCLA Hematology/Oncology - Santa Monica ( Site 0013), Los Angeles, California, United States
🇺🇸
Miami VA Healthcare System ( Site 0024), Miami, Florida, United States

and more 202 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy